News

The earlier collaboration between the two firms focused on the discovery of new treatments for neuropsychiatric disorders, while the new three-year deal will focus on investigating new medicines

HD is caused by the progressive breakdown of nerve cells in the brain that affects about five to seven people per 100,000 in western countries, according to the

G1T28 is an intravenous (IV) therapy being studied as a bone marrow and immune system chemoprotectant in patients with SCLC who are receiving chemotherapy. The two Phase 1b/2a

Centyrins are a class of Janssen proprietary alternative scaffold molecules that can be engineered to bind to target proteins with an interface of similar size to those used

Brintellix was discovered by Lundbeck researchers and the clinical trial program in the US was conducted jointly by the two firms, while Takeda holds the NDA for the

"Immuno-oncology has emerged as a particularly promising field to create potentially curative treatment options for many cancer patients," said Victoria Richon, Vice-President and Head of Cancer Research, Discovery

Both the firms will collaborate on seeking regulatory approval from Australia’s Therapeutic Goods Administration (TGA) and New Zealand’s Medicines and Medical Devices Safety Authority (Medsafe). As part of

Manapol is a pure, premium, 100 percent aloe vera gel extract, designed to support cell-to-cell communication.* Mannatech’s offering has a guaranteed molecular weight of more than one million

Under the deal, DKSH will be responsible for providing regulatory, distribution and logistics services for Actelion in Hong Kong, Malaysia and Singapore. Initially, the deal covers Tracleer, a